FXH moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend. In 37 of 40 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FXH as a result. In 79 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for FXH turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 38 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FXH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The RSI Indicator entered the oversold zone -- be on the watch for FXH's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for FXH crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +4.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where FXH advanced for three days, in 239 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
FXH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 206 of 265 cases where FXH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
GMED moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend. In 28 of 43 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 65%.
The 10-day RSI Indicator for GMED moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 20 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 59%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GMED as a result. In 48 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.
The Moving Average Convergence Divergence Histogram (MACD) for GMED turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 26 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 52%.
The 10-day moving average for GMED crossed bearishly below the 50-day moving average on November 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMED advanced for three days, in 203 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
GMED may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 121 of 211 cases where GMED Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.000) is normal, around the industry mean (4.142). P/E Ratio (17.897) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.493) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.275) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. GMED’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
GMED | ||
|---|---|---|
OUTLOOK RATING 1..100 | 70 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 73 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 65 | |
PRICE GROWTH RATING 1..100 | 73 | |
P/E GROWTH RATING 1..100 | 83 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| FXH | GMED | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 59% |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 72% |
| Momentum ODDS (%) | 2 days ago 78% | 2 days ago 53% |
| MACD ODDS (%) | 2 days ago 81% | 2 days ago 52% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 58% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 59% |
| Advances ODDS (%) | 18 days ago 77% | 18 days ago 66% |
| Declines ODDS (%) | 2 days ago 79% | 2 days ago 57% |
| BollingerBands ODDS (%) | 2 days ago 80% | 2 days ago 62% |
| Aroon ODDS (%) | 2 days ago 78% | 2 days ago 57% |
A.I.dvisor indicates that over the last year, FXH has been loosely correlated with GMED. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if FXH jumps, then GMED could also see price increases.
| Ticker / NAME | Correlation To FXH | 1D Price Change % | ||
|---|---|---|---|---|
| FXH | 100% | -1.20% | ||
| GMED - FXH | 63% Loosely correlated | -2.49% | ||
| NVST - FXH | 59% Loosely correlated | -1.55% | ||
| STE - FXH | 58% Loosely correlated | +0.39% | ||
| TXG - FXH | 58% Loosely correlated | -9.72% | ||
| ZBH - FXH | 57% Loosely correlated | -0.36% | ||
More | ||||